Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events
S Singer, SY Tan, AK Dewan, M Davids… - Journal of the American …, 2023 - Elsevier
Background Ibrutinib is an oral inhibitor of Bruton tyrosine kinase that is approved by the
United States Food and Drug Administration for several lymphoproliferative disorders and
chronic graft-versus-host disease. Objective To characterize cutaneous eruptions arising
from ibrutinib and highlight overlap with epidermal growth factor receptor (EGFR) inhibitor–
induced dermatologic adverse events. Methods Single-center retrospective cohort of
patients referred to the Skin Toxicities Program for treatment of cutaneous eruptions while …
United States Food and Drug Administration for several lymphoproliferative disorders and
chronic graft-versus-host disease. Objective To characterize cutaneous eruptions arising
from ibrutinib and highlight overlap with epidermal growth factor receptor (EGFR) inhibitor–
induced dermatologic adverse events. Methods Single-center retrospective cohort of
patients referred to the Skin Toxicities Program for treatment of cutaneous eruptions while …
以上显示的是最相近的搜索结果。 查看全部搜索结果